Uterine artery embolization of large fibroids

Comparative study of procedure with and without pretreatment gonadotropin-releasing hormone agonists

ManDeuk Kim, Myungsu Lee, Mu Sook Lee, Sung Il Park, Jong Yun Won, Do Yun Lee, Kwang Hun Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE. The purpose of this study was to evaluate the safety of pretreatment with gonadotropin-releasing hormone (GnRH) agonists before uterine artery embolization (UAE) of large fibroids. MATERIALS AND METHODS. The cases of 40 patients with large fibroids (≥ 10 cm) were retrospectively analyzed. Among the 40 patients, 28 (control group) underwent UAE without pretreatment with GnRH agonists, and 12 (GnRH group) received GnRH agonists 1-5 times before UAE. MRI was used to assess necrosis of large fibroids and their volumes in both groups within 3 months after UAE. RESULTS. Complete necrosis of large fibroids after UAE was achieved in 39 of 40 patients (97.5%). Only one patient, who was in the control group, had incomplete necrosis of the predominant fibroid. When GnRH agonists were administered before UAE, the mean volume reduction rate of fibroids was 36.3%. The final mean volume reduction rates of the predominant fibroids and the uterus after UAE in the GnRH group were 56.5% (range, 38-79%) and 50.8% (range, 35-72%), significantly higher than the volume reduction rates of 35.1% (range, 7-65%) and 34.9% (range, 16-54%) in the control group (p < 0.001). Grade D complications were not seen in the GnRH group but occurred in four patients in the control group. CONCLUSION. Pretreatment with GnRH agonists before UAE of large fibroids was safe for patients with large fibroids and did not prevent performance of UAE.

Original languageEnglish
Pages (from-to)441-446
Number of pages6
JournalAmerican Journal of Roentgenology
Volume199
Issue number2
DOIs
Publication statusPublished - 2012 Aug 1

Fingerprint

Uterine Artery Embolization
Leiomyoma
Gonadotropin-Releasing Hormone
Control Groups
Necrosis
Safety

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Kim, ManDeuk ; Lee, Myungsu ; Lee, Mu Sook ; Park, Sung Il ; Won, Jong Yun ; Lee, Do Yun ; Lee, Kwang Hun. / Uterine artery embolization of large fibroids : Comparative study of procedure with and without pretreatment gonadotropin-releasing hormone agonists. In: American Journal of Roentgenology. 2012 ; Vol. 199, No. 2. pp. 441-446.
@article{bb7d560066b543f183c05abb67009fbe,
title = "Uterine artery embolization of large fibroids: Comparative study of procedure with and without pretreatment gonadotropin-releasing hormone agonists",
abstract = "OBJECTIVE. The purpose of this study was to evaluate the safety of pretreatment with gonadotropin-releasing hormone (GnRH) agonists before uterine artery embolization (UAE) of large fibroids. MATERIALS AND METHODS. The cases of 40 patients with large fibroids (≥ 10 cm) were retrospectively analyzed. Among the 40 patients, 28 (control group) underwent UAE without pretreatment with GnRH agonists, and 12 (GnRH group) received GnRH agonists 1-5 times before UAE. MRI was used to assess necrosis of large fibroids and their volumes in both groups within 3 months after UAE. RESULTS. Complete necrosis of large fibroids after UAE was achieved in 39 of 40 patients (97.5{\%}). Only one patient, who was in the control group, had incomplete necrosis of the predominant fibroid. When GnRH agonists were administered before UAE, the mean volume reduction rate of fibroids was 36.3{\%}. The final mean volume reduction rates of the predominant fibroids and the uterus after UAE in the GnRH group were 56.5{\%} (range, 38-79{\%}) and 50.8{\%} (range, 35-72{\%}), significantly higher than the volume reduction rates of 35.1{\%} (range, 7-65{\%}) and 34.9{\%} (range, 16-54{\%}) in the control group (p < 0.001). Grade D complications were not seen in the GnRH group but occurred in four patients in the control group. CONCLUSION. Pretreatment with GnRH agonists before UAE of large fibroids was safe for patients with large fibroids and did not prevent performance of UAE.",
author = "ManDeuk Kim and Myungsu Lee and Lee, {Mu Sook} and Park, {Sung Il} and Won, {Jong Yun} and Lee, {Do Yun} and Lee, {Kwang Hun}",
year = "2012",
month = "8",
day = "1",
doi = "10.2214/AJR.11.7220",
language = "English",
volume = "199",
pages = "441--446",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "2",

}

Uterine artery embolization of large fibroids : Comparative study of procedure with and without pretreatment gonadotropin-releasing hormone agonists. / Kim, ManDeuk; Lee, Myungsu; Lee, Mu Sook; Park, Sung Il; Won, Jong Yun; Lee, Do Yun; Lee, Kwang Hun.

In: American Journal of Roentgenology, Vol. 199, No. 2, 01.08.2012, p. 441-446.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Uterine artery embolization of large fibroids

T2 - Comparative study of procedure with and without pretreatment gonadotropin-releasing hormone agonists

AU - Kim, ManDeuk

AU - Lee, Myungsu

AU - Lee, Mu Sook

AU - Park, Sung Il

AU - Won, Jong Yun

AU - Lee, Do Yun

AU - Lee, Kwang Hun

PY - 2012/8/1

Y1 - 2012/8/1

N2 - OBJECTIVE. The purpose of this study was to evaluate the safety of pretreatment with gonadotropin-releasing hormone (GnRH) agonists before uterine artery embolization (UAE) of large fibroids. MATERIALS AND METHODS. The cases of 40 patients with large fibroids (≥ 10 cm) were retrospectively analyzed. Among the 40 patients, 28 (control group) underwent UAE without pretreatment with GnRH agonists, and 12 (GnRH group) received GnRH agonists 1-5 times before UAE. MRI was used to assess necrosis of large fibroids and their volumes in both groups within 3 months after UAE. RESULTS. Complete necrosis of large fibroids after UAE was achieved in 39 of 40 patients (97.5%). Only one patient, who was in the control group, had incomplete necrosis of the predominant fibroid. When GnRH agonists were administered before UAE, the mean volume reduction rate of fibroids was 36.3%. The final mean volume reduction rates of the predominant fibroids and the uterus after UAE in the GnRH group were 56.5% (range, 38-79%) and 50.8% (range, 35-72%), significantly higher than the volume reduction rates of 35.1% (range, 7-65%) and 34.9% (range, 16-54%) in the control group (p < 0.001). Grade D complications were not seen in the GnRH group but occurred in four patients in the control group. CONCLUSION. Pretreatment with GnRH agonists before UAE of large fibroids was safe for patients with large fibroids and did not prevent performance of UAE.

AB - OBJECTIVE. The purpose of this study was to evaluate the safety of pretreatment with gonadotropin-releasing hormone (GnRH) agonists before uterine artery embolization (UAE) of large fibroids. MATERIALS AND METHODS. The cases of 40 patients with large fibroids (≥ 10 cm) were retrospectively analyzed. Among the 40 patients, 28 (control group) underwent UAE without pretreatment with GnRH agonists, and 12 (GnRH group) received GnRH agonists 1-5 times before UAE. MRI was used to assess necrosis of large fibroids and their volumes in both groups within 3 months after UAE. RESULTS. Complete necrosis of large fibroids after UAE was achieved in 39 of 40 patients (97.5%). Only one patient, who was in the control group, had incomplete necrosis of the predominant fibroid. When GnRH agonists were administered before UAE, the mean volume reduction rate of fibroids was 36.3%. The final mean volume reduction rates of the predominant fibroids and the uterus after UAE in the GnRH group were 56.5% (range, 38-79%) and 50.8% (range, 35-72%), significantly higher than the volume reduction rates of 35.1% (range, 7-65%) and 34.9% (range, 16-54%) in the control group (p < 0.001). Grade D complications were not seen in the GnRH group but occurred in four patients in the control group. CONCLUSION. Pretreatment with GnRH agonists before UAE of large fibroids was safe for patients with large fibroids and did not prevent performance of UAE.

UR - http://www.scopus.com/inward/record.url?scp=84864757308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864757308&partnerID=8YFLogxK

U2 - 10.2214/AJR.11.7220

DO - 10.2214/AJR.11.7220

M3 - Article

VL - 199

SP - 441

EP - 446

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 2

ER -